Health

The Widely Available Low-Cost Drug That Could Fight COVID-19

Human Lungs Illustration

A widely available and affordable drug, heparin, limits lung damage when inhaled by COVID-19 patients, according to world-first findings by researchers from The Australian National University (ANU).

The researchers are coordinating multiple studies tracking hospital patients infected with SARS-CoV-2 in 13 countries who were given doses of inhaled heparin.

ANU study lead Professor Frank van Haren said initial results indicate the drug could be “a promising treatment” and also “a possible preventative against the virus.”

Breathing and oxygen levels improved in 70 percent of the patients after they inhaled a course of heparin, and their symptoms improved according to the World Health Organization (WHO) COVID symptoms scale.

Professor Frank van Haren, The Australian National University. Credit: ANU

“There is still an urgent need for an effective treatment of COVID-19 and the early results of our trials show inhaled heparin is safe and effective,” Professor van Haren said.

“This drug is already available in hospitals all over the world and it is a very inexpensive drug. If it is as effective as our early results suggest, it could have a major impact in our fight against COVID.”

Heparin, which is normally administered via injection, is a blood thinner used to treat and prevent blood clots across the world and is said to be widely available.

Co-author Professor Clive Page, from King’s College London, who is co-leading the global studies, said: “Inhaled heparin has antiviral properties which work by binding to the spike proteins the coronavirus uses to enter the cells of the body.

“Inhaled heparin effectively stops the virus infecting cells in the lungs and could also stop people from getting the virus from others.

“It also works as an anti-inflammatory drug — the medicine has the ability to calm everything down when the body is mounting an exaggerated response to the virus. We already know heparin can reduce lung damage caused by this inflammation and the immune response overdrive that we see in other lung diseases which could provide benefit to patients hospitalized with COVID-19.

“It’s also a blood thinner. When COVID-19 patients get very sick they develop blood clots in the lungs and these can be lethal. Heparin stops these clots from forming. There is no other drug that has these three different effects — anti-viral, anti-inflammatory and anti-coagulant.”

The researchers say because the drug has antiviral properties and calms the immune system down it could be used at different stages of treatment.

When inhaled, heparin also shows promise as a preventative and could be used to boost vaccination efforts.

“Most COVID experts agree that vaccination alone is not going to stop the pandemic. This could really assist in poorer countries where vaccination is challenging and we think it could help front line workers who could use it as a preventative measure,” Professor van Haren said.

“Inhaled heparin is a promising new possibility to provide a low-cost, safe and effective treatment for COVID-19 that is available and affordable to low and middle-income countries around the globe.”

Professor van Haren said the team was now collecting more evidence that inhaled heparin works as a treatment and prevention for COVID-19.

“Once we have this evidence, heparin via inhalation could be an option to treat COVID-19 patients, everywhere, within months,” he said.

The findings from the first 98 patients in the studies are published in a new paper in the British Journal of Clinical Pharmacology.

Reference: “Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients” by Frank M. P. van Haren, Lex M. van Loon, Anne Steins, Thomas L. Smoot, Caitlin Sas, Sabrina Staas, Alicia B. Vilaseca, Ruben A. Barbera, Gustavo Vidmar, Hugo Beccari, Frida Popilevsky, Eleonora Daribayeva, Bhuvaneshwari Venkatesan, Susan Mozes, Rachel Postel, Natalie Popilevski, Andrew Webb, Quentin Nunes, John G. Laffey, Antonio Artigas, Roger Smith, Barry Dixon, Alice Richardson, Hwan-Jin Yoon and Clive Page, 4 January 2022, British Journal of Clinical Pharmacology.
DOI: 10.1111/bcp.15212

Share

View Comments

  • Oh, wait, since a certain president of the United States hasn't mentioned this, you mean that a simple affordable solution is found?
    Like, um, that unspeakable word: i-mer-vic-tin or hy-droxy-.... Geeshe, science has really come a long way since the dark ages of 2020!

By
Australian National University

Recent Posts

At Risk for Diabetes? Scientists Recommend Doing This

A new study recommends cutting carbs.  Although low-carb diets are often recommended for individuals who…

November 29, 2022

NASA Assesses Launch Pad for Damage After Launch of the World’s Most Powerful Rocket

Following the successful Artemis I liftoff of the world’s most powerful rocket from NASA’s Kennedy…

November 29, 2022

History-Making Event: Orion Goes the (Max) Distance – 268,563 Miles From Earth

NASA Artemis I — Flight Day 13: Orion Goes the (Max) Distance Just after 3…

November 29, 2022

Autism Breakthrough: New Treatment Significantly Improves Social Skills and Brain Function

The treatment caused neurological changes, including a decrease in inflammation and an increase in functionality,…

November 29, 2022

Seemingly Impossible: Nanostructure Compresses Light 10,000 Times Thinner Than a Human Hair

This major scientific advance has implications for many fields, including energy-efficient computers and quantum technology.…

November 29, 2022

“Profound Implications” – New Research Details the Microbial Origins of Type 1 Diabetes

A bacterial protein stimulates the reproduction of insulin-producing cells, pointing to a potential treatment. Nearly…

November 29, 2022